Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications

Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Jiamei LianChao Deng

Abstract

Second generation antipsychotic drugs (SGAs) cause substantial body weight gain/obesity and other metabolic side-effects such as dyslipidaemia. Their antagonistic affinity to the histaminergic H1 receptor (H1R) has been identified as one of the main contributors to weight gain/obesity side-effects. The effects and mechanisms of betahistine (a histaminergic H1R agonist and H3 receptor antagonist) have been investigated for ameliorating SGA-induced weight gain/obesity in both animal models and clinical trials. It has been demonstrated that co-treatment with betahistine is effective in reducing weight gain, associated with olanzapine in drug-naïve patients with schizophrenia, as well as in the animal models of both drug-naïve rats and rats with chronic, repeated exposure to olanzapine. Betahistine co-treatment can reduce food intake and increase the effect of thermogenesis in brown adipose tissue by modulating hypothalamic H1R-NPY-AMPKα (NPY: neuropeptide Y; AMPKα: AMP-activated protein kinase α) pathways, and ameliorate olanzapine-induced dyslipidaemia through modulation of AMPKα-SREBP-1-PPARα-dependent pathways (SREBP-1: Sterol regulatory element binding protein 1; PPARα: Peroxisome proliferator-activated receptor-α) in the live...Continue Reading

References

Jan 1, 1975·Psychopharmacologia·T Silverstone, D Schuyler
Jan 1, 1988·Physiology & Behavior·N ItowiH Wada
Nov 1, 1993·Comparative Biochemistry and Physiology. C, Comparative Pharmacology and Toxicology·D LarhammarC Söderberg
May 20, 1998·Nature·P KristensenS Hastrup
Nov 3, 1998·Biological Psychiatry·D A WirshingW C Wirshing
Dec 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·C BrobergerT Hökfelt
Jan 6, 2001·Molecular Endocrinology·W A NijenhuisR A Adan
Feb 13, 2001·Progress in Neurobiology·R E BrownH L Haas
May 16, 2001·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·A FossatiC Benvenuti
Dec 26, 2001·Molecular Pharmacology·Jordi Gomez-RamirezIsaac Blanco
Feb 13, 2002·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·G J Morton, M W Schwartz
Feb 19, 2002·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·F Rohner-JeanrenaudJ F Caro
Apr 2, 2002·The American Journal of Psychiatry·John A MorrisonBruce A Barton
Dec 19, 2002·The Journal of Clinical Investigation·Kazuhiko TakahashiHidehito Kotani
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wesley K KroezeBryan L Roth
Apr 1, 2004·American Journal of Medical Genetics. Part a·Daniel L MarksRoger D Cone
May 12, 2004·Peptides·Sarah F Leibowitz, Katherine E Wortley
Oct 8, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Sarah ThrelfellSusan A Greenfield
Nov 16, 2004·Trends in Endocrinology and Metabolism : TEM·Erin E JobstMichael A Cowley
Apr 28, 2005·Nature Neuroscience·Roger D Cone
May 18, 2005·Obesity Research·Richard L BradleyEleftheria Maratos-Flier
Jun 15, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Gavin P ReynoldsZhi Jun Zhang
Sep 15, 2005·Nature Neuroscience·Eva GroppJens C Brüning
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Sep 27, 2005·Physiological Reviews·Sarah StanleyStephen Bloom

❮ Previous
Next ❯

Citations

Jun 16, 2016·Frontiers in Neuroscience·Mohammad A KhanfarHolger Stark
Sep 7, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Virginio SalviFrancesco Barone-Adesi
Nov 20, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Arun K TiwariDaniel J Müller
Dec 7, 2017·Frontiers in Neuroscience·Jiezhong ChenChao Deng
Oct 1, 2019·Expert Opinion on Drug Safety·Wade MarteeneDan Siskind
Jun 18, 2019·American Journal of Therapeutics·Ahmed NaguySulaiman AlKhadhari
Jun 15, 2019·Psychopharmacology·Marina GarrigaClemente García-Rizo
Jun 8, 2018·Angiology·Theodora A ManolisAntonis S Manolis
May 29, 2019·Clinical Neuropharmacology·Michael Poyurovsky, Abraham Weizman
Sep 25, 2019·American Journal of Physiology. Endocrinology and Metabolism·Ya-Xin ZhaoShu-Wen Qian
Feb 6, 2019·International Journal of Molecular Sciences·Ching-Ping YangWen-Ying Chen
Mar 30, 2021·Frontiers in Psychiatry·Mark R Libowitz, Erika L Nurmi
Apr 13, 2021·Journal of Clinical Psychopharmacology·Satish SuhasGanesan Venkatasubramanian
Jul 7, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Kamil MikaMagdalena Kotańska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here